文献速递儿科与产科急症心脑血管急症重症综合管理与镇静镇痛

法国巴黎新冠疫情期间川崎病样多系统炎症综合征:前瞻性观察研究

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.
PubMed 文献 · BMJ · 2020-06-03
一句话结论2020年4–5月巴黎21例川崎病样多系统炎症综合征患儿中90%有近期SARS-CoV-2感染证据,81%需ICU支持,全部出院。

该前瞻性观察研究纳入2020年4月27日至5月11日巴黎某大学医院普通儿科收治的21例≤18岁川崎病特征患儿,随访至出院。中位年龄7.9岁,57%为非裔,57%表现为川崎病休克综合征,76%并心肌炎,81%需重症监护。全部患儿早期均有明显胃肠道症状及高炎症标志物;90%有近期SARS-CoV-2感染证据。全部接受静脉注射免疫球蛋白,48%加用糖皮质激素,临床结局均良好,24%住院期间检出中度冠状动脉扩张。

要点

  • 2020年4月27日至5月11日15天内,巴黎某大学医院普通儿科收治21例≤18岁川崎病特征患儿,中位年龄7.9岁(范围3.7–16.6),57%为非裔。
  • 12例(57%)表现为川崎病休克综合征,16例(76%)并心肌炎,17例(81%)需重症监护支持。
  • 全部21例早期均有明显胃肠道症状和高水平炎症标志物。
  • 19例(90%)有近期SARS-CoV-2感染证据:RT-PCR阳性8/21,IgG抗体阳性19/21。
  • 全部接受静脉注射免疫球蛋白,10例(48%)加用糖皮质激素;全部临床结局良好,5例(24%)住院期间检出中度冠状动脉扩张。

适用人群与场景

  • 2020年4月27日至5月11日入住巴黎某大学医院普通儿科、年龄≤18岁、具有川崎病特征的儿童和青少年,共21例,随访至2020年5月15日出院。

处置流程与药物剂量

  • 全部21例患儿均接受静脉注射免疫球蛋白治疗,其中10例(48%)同时接受糖皮质激素治疗。

红旗征与不能漏的情况

  • 川崎病休克综合征:12例(57%)出现,需识别并升级监护。
  • 心肌炎:16例(76%)出现。
  • 需重症监护支持:17例(81%)。

研究设计与关键结果

  • 前瞻性观察研究,单中心(巴黎某大学医院普通儿科),纳入21例≤18岁具有川崎病特征的患儿,中位年龄7.9岁(范围3.7–16.6),12例(57%)为非裔。
  • 12例(57%)表现为川崎病休克综合征,16例(76%)并心肌炎,17例(81%)需重症监护支持。
  • 全部21例早期均有明显胃肠道症状和高水平炎症标志物。
  • 19例(90%)有近期SARS-CoV-2感染证据:鼻咽拭子RT-PCR阳性8/21,血清IgG抗体阳性19/21。
  • 全部接受静脉注射免疫球蛋白,10例(48%)加用糖皮质激素;全部临床结局良好。
  • 5例(24%)住院期间检出中度冠状动脉扩张。
  • 截至2020年5月15日,住院8天(范围5–17天)后全部出院回家。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,巴黎地区儿童和青少年中持续发生的川崎病样多系统炎症综合征暴发可能与SARS-CoV-2相关。
  • 作者指出,本研究中受累儿童和青少年出现胃肠道症状、川崎病休克综合征及非裔比例异常高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a potential temporal association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

DESIGN: Prospective observational study.

SETTING: General paediatric department of a university hospital in Paris, France.

PARTICIPANTS: 21 children and adolescents (aged ≤18 years) with features of Kawasaki disease who were admitted to hospital between 27 April and 11 May 2020 and followed up until discharge by 15 May 2020.

MAIN OUTCOME MEASURES: The primary outcomes were clinical and biological data, imaging and echocardiographic findings, treatment, and outcomes. Nasopharyngeal swabs were prospectively tested for SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR) and blood samples were tested for IgG antibodies to the virus.

RESULTS: 21 children and adolescents (median age 7.9 (range 3.7-16.6) years) were admitted with features of Kawasaki disease over a 15 day period, with 12 (57%) of African ancestry. 12 (57%) presented with Kawasaki disease shock syndrome and 16 (76%) with myocarditis. 17 (81%) required intensive care support. All 21 patients had noticeable gastrointestinal symptoms during the early stage of illness and high levels of inflammatory markers. 19 (90%) had evidence of recent SARS-CoV-2 infection (positive RT-PCR result in 8/21, positive IgG antibody detection in 19/21). All 21 patients received intravenous immunoglobulin and 10 (48%) also received corticosteroids. The clinical outcome was favourable in all patients. Moderate coronary artery dilations were detected in 5 (24%) of the patients during hospital stay. By 15 May 2020, after 8 (5-17) days of hospital stay, all patients were discharged home.

CONCLUSIONS: The ongoing outbreak of Kawasaki-like multisystem inflammatory syndrome among children and adolescents in the Paris area might be related to SARS-CoV-2. In this study an unusually high proportion of the affected children and adolescents had gastrointestinal symptoms, Kawasaki disease shock syndrome, and were of African ancestry.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020. PMID: 32493739. doi:10.1136/bmj.m2094

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。